ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Articles tagged "Rejection"

  • 2022 American Transplant Congress

    Local Intragraft Humoral Immune Response in Chronic Lung Allograft Dysfunction

    E. Miyamoto1, S. C. Juvet2, D. Vosoughi2, J. Wang2, J. Al-Refaee2, T. Daigneault2, A. Duong2, S. Moshkelgosha2, S. Keshavjee2, K. Tinckam2, A. Chruscinski3, D. Hwang4, T. Martinu2

    1Tenri Hospital Japan, University Health Network Canada, Nara, Japan, 2University Health Network, Toronto, ON, Canada, 3Multi-Organ Transplantation, University Health Network, Toronto, ON, Canada, 4Sunnybrook Health Science Centre, Toronto, ON, Canada

    *Purpose: Donor HLA-specific antibody (DSA) and antibody against self-antigens (self-antigen antibody) can cause injury and lead to chronic lung allograft dysfunction (CLAD) after lung transplantation…
  • 2022 American Transplant Congress

    Utility of a Holistic Molecular Paradigm for Kidney Biopsy in the Clinic

    S. Anand1, J. Sanchez-Garcia1, K. Qui2, K. Pinney2, A. Raza1, T. Srinivas2, D. Morris1

    1Intermountain Medical Center, Murray, UT, 2CareDX, South San Francisco, CA

    *Purpose: We report on the clinical utility of a serial dd-cfDNA (donor derived cell free DNA) monitoring coupled with Tissue Transcriptomics (Tr) and Histology (Hx)…
  • 2022 American Transplant Congress

    A Novel Approach to Non-Invasive Multimodality Testing with Allosure and Allomap Predicts Microvascular Inflammation with High Accuracy in Kidney Transplant Recipients

    S. Parajuli, F. Aziz, N. Garg, S. E. Panzer, K. Van Hyfte, K. Degner, S. Reese, L. Ptak, N. Wilson, A. Djamali

    University of Wisconsin, Madison, WI

    *Purpose: The most prominent histologic lesion in antibody-mediated rejection (ABMR) is microvascular inflammation (MVI); however, its recognition and scoring can be challenging and poorly reproducible…
  • 2022 American Transplant Congress

    Outcomes in Renal Transplant Recipients Receiving Pre-Transplant Financial Assistance Through the American Kidney Fund

    H. Roppo1, P. Klem1, B. Crowther1, E. Sartain1, K. Schoeppler1, P. T. Kennealey2, B. Kaplan3

    1Department of Pharmacy, University of Colorado Hospital, Aurora, CO, 2Department of Surgery, University of Colorado Hospital, Aurora, CO, 3Department of Renal Med Diseases/Hypertension, University of Colorado Hospital, Aurora, CO

    *Purpose: Pre-transplant financial assistance for insurance premiums is available for eligible patients through the American Kidney Fund (AKF), but this funding ends within the first…
  • 2022 American Transplant Congress

    Direct Comparison of Clinical Outcomes with Belatacept-Based Regimens to Calcineurin Inhibitors Among DCD and/or High KDPI Kidney Transplant Recipients

    A. Rizvi1, M. Kueht2, S. Hussain3, J. Fair2, R. Ramirez4, A. Gamilla-Crudo5, M. Mujtaba5

    1Internal Medicine, Nephrology, University of Texas Medical Branch at Galveston, Galveston, TX, 2Surgery, University of Texas Medical Branch, Galveston, TX, 3University of Texas Medical Branch, Houston, TX, 4Surgery, University of Texas Medical Branch at Galveston, Galveston, TX, 5University of Texas Medical Branch, Galveston, TX

    *Purpose: Belatacept, an inhibitor of the T-cell costimulatory pathway, can be used in recipients of Donation after Cardiac Death (DCD) and high Kidney Donor Profile…
  • 2022 American Transplant Congress

    Month 1 Donor Derived Cell Free DNA Levels Predict Future Kidney Transplant Rejection

    B. M. Kinsella1, K. Guo1, C. Rebello1, L. Zhao1, S. Park2, J. Friedewald1

    1Northwestern University, Chicago, IL, 2Transplant Nephrology, Northwestern University, Chicago, IL

    *Purpose: The purpose of this study was to determine if donor-derived cell-free DNA (dd-cfDNA) can be used one-month post-transplant to predict later allograft rejection.*Methods: Retrospective…
  • 2022 American Transplant Congress

    Impact of Delayed Graft Function in Donation After Circulatory Death Kidney Transplantation

    J. Mello Offerni1, H. Brar1, D. Lee1, M. Levine2, M. Mandurah1, S. Rim1, A. Sener1, P. Luke1

    1Urology, Western University, London, ON, Canada, 2Division of Urology, Department of Surgery, University of Alberta, Edmonton, AB, Canada

    *Purpose: Donation after circulatory death (DCD) has been associated with higher rates of delayed graft function (DGF) when compared to donation after brain death (DBD).…
  • 2022 American Transplant Congress

    DEPTOR: A Novel Endothelial-Specific Regulator of Cell-Intrinsic Anti-Inflammation Following Transplantation

    C. Testini1, S. Bose1, K. Liu1, S. Kong1, E. Flynn1, M. Miovski1, J. Leyva-Rangel1, M. Laplante2, J. Wedel1, D. M. Briscoe1

    1Boston Children's Hospital and Harvard Medical School, Boston, MA, 2Laval University, Quebec, QC, Canada

    *Purpose: Recent studies have highlighted a paradigm whereby the maintenance of normal tissue homeostasis and the prevention of chronic inflammation is dependent on the active…
  • 2022 American Transplant Congress

    A Single-Center’s Outcomes of Combined Heart-Liver Transplantation

    R. W. Lincoln1, K. Kalvakuri2, A. Guha2, A. Bhimaraj2, E. E. Suarez2, A. Saharia3, C. M. Mobley3, F. Amirkhosravi3, J. Krisl1

    1Pharmacy, Houston Methodist Hospital, Houston, TX, 2DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, 3Surgery, Houston Methodist Hospital, Houston, TX

    *Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…
  • 2022 American Transplant Congress

    Circulating Donor-Derived Cell-Free DNA: A Novel Non-Invasive Biomarker for Immune Surveillance in Vascularized Composite Allotransplantation

    W. J. Rifkin1, J. Trilles1, P. S. Rabbani1, O. C. Onuh1, B. E. Gelb2, D. J. Ceradini1, E. D. Rodriguez1

    1Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY, 2Transplant Institute, NYU Langone Health, New York, NY

    *Purpose: The purpose of this study is to evaluate whether circulating donor-derived cell-free DNA (dd-cfDNA) could be used as a noninvasive biomarker to detect rejection…
  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 172
  • Next Page »

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences